|本期目录/Table of Contents|

[1]徐庆祝,牛远杰.Gleason 10分前列腺癌患者临床特点分析[J].天津医科大学学报,2017,23(04):361-363.
 XU Qing-zhu,NIU Yuan-jie.Clinical and pathological research of prostate cancer with Gleason score 10[J].Journal of Tianjin Medical University,2017,23(04):361-363.
点击复制

Gleason 10分前列腺癌患者临床特点分析(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
23卷
期数:
2017年04期
页码:
361-363
栏目:
临床医学
出版日期:
2017-07-02

文章信息/Info

Title:
Clinical and pathological research of prostate cancer with Gleason score 10
文章编号:
1006-8147(2017)04-0361-03
作者:
徐庆祝12牛远杰1
(1.天津医科大学第二医院泌尿外科,天津市泌尿外科研究所,天津 300211; 2.天津市津南区咸水沽医院泌尿外科,天津 300350)
Author(s):
XU Qing-zhu12 NIU Yuan-jie1
(1.Department of Urology, The Second Hospital , Tianjin Medical University, Tianjin 3002112,China;2.Department of Urology,Xianshui-gu Hospital,Jinnan District, Tianjin 300350,China)
关键词:
前列腺癌Gleason评分临床病理特点
Keywords:
prostate cancer Gleason score clinical and pathological characteristic
分类号:
R737.25
DOI:
-
文献标志码:
A
摘要:
目的:探讨Gleason 10分前列腺癌患者的临床病理学特点。方法:对30例临床病理资料完整的Gleason 10分前列腺癌患者的相关资料进行回顾性分析。结果:前列腺癌患者平均年龄71.9岁,组织标本病理分级均为Gleason 10分, ECT示骨转移患者10例,肺转移患者1例。血清总前列腺特异抗原平均56.35 ng/mL,平均前列腺特异抗原密度为0.57。患者体质指数(BMI)均值为23.90,大于25的患者有14位,占总数47%。结论:Gleason 10分前列腺癌患者发病年龄较大,平均血清总前列腺特异抗原水平及前列腺特异抗原密度较高,常伴有精囊侵袭、骨转移及远处转移。
Abstract:
Objective To investigate the clinical and pathological features of prostate cancer patients with Gleason score 10 . MethodsThirty cases of prostate cancer with 10 Gleason score were reviewed to analyze the clinical and pathological factors. ResultsAll the post-pathological results confirmed the diagnosis of prostate cancer with 10 Gleason score. The average age was 71.9, and ECT examination showed 10 patients with bone metastasis, one with lung metastasis. Mean value of total serum PSA was 56.35 ng/m and average PSAD was 0.57. Mean BMI was 23.90, but there were 14 patients with a BMI higher than 25, accounting for 47% of the total. ConclusionThe study showed that prostate cancer patients with 10 Gleason score are usually found in elder men, with higher levels of total PSA and PSAD. Simultaneously, 10 Gleason score prostate cancer patients commonly have seminal vesicles, bones and distant sites metastasis.

参考文献/References:

[1]Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J].CA Cancer J Clin,2015,65(1):5

[2]韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330

[3]Siegel R, Ma J M, Zou Z H, et al. Cancer statistics, 2014[J].CA Cancer J Clin,2014,64(1):9

[4]Gleason D.Histologic grading of prostate cancer: a perspective[J].Hum Pathol,1992,23(3):273

[5]Rubin M, Girelli G, Demichelis F. Genomic correlates to the newly proposed grading prognostic groups for prostate cancer[J].Eur Urol,2016,69(4):557

[6]Vira M, Guzzo T, Heitjan D, et al. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known[J].BJU Int,2008,101(10):1232

[7]Lau W, Blute M, Bostwick D, et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4[J].J Urol,2001, 166(5):1692

[8]Gleason D F. Classification of prostatic carcinomas[J].Cancer Chemother Rep,1966,50(3):125

[9]Wright J, Salinas C, Lin D, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort[J].J Urol,2009,182(6):2702

[10]彭鹏,龚杨明,鲍萍萍,等.中国2008年前列腺癌发病、死亡和患病情况的估计及预测[J].中华流行病学杂志,2012,33(10):1056

[11]Kelly T, Yang W, Chen C S, et al. Global burden of obesity in 2005 and projections to 2030[J].Int J Obes (Lond),2008,32(9):1431

[12]Calle E E, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults[J].N Engl J Med,2003,348(17):1625

[13] Bassett J K, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality[J]. Int J Cancer,2012,131(7):1711

[14]Bai P, Hu M, Xu H, et al. Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis[J].World J Surg Oncol,2015,13(1):311

[15]Rietbergen J, Hoedemaeker R, Kruger A, et al. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study[J].J Urol,1999,161(4):1192

[16]Kim E, Andriole G. Prostate-specific antigen-based screening: controversy and guidelines[J].BMC Med,2015,13:61

[17]Kim S, Jeong T, Yoo D, et al. Can Prostate-Specific antigen kinetics before prostate biopsy predict the malignant potential of prostate cancer[J].Yonsei Med J,2015,56(6):1492

[18]Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer[J].Eur J Cancer,2013,49(13):2949

[19]Tosoian J, Reyes D, Gorin M, et al. A novel approach for performing bone marrow aspiration at the time of radical prostatectomy[J]. Urol Case Rep.2016,6(6):45

[20]Scosyrev E, Messing E, Mohile S, et al. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality[J].Cancer,2012,118(12):3062

[21]Hess K R, Varadhachary G R, Taylor S H, et al. Metastatic patterns in adenocarcinoma[J].Cancer,2006,106(7):1624

[22]Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis[J].Prostate,2014,74(2):210

[23]Sauter G, Steurer S, Clauditz T, et al. Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens[J].Eur Urol,2016,69(4):592

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
 YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(04):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
 WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(04):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
 ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(04):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
 SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(04):401.
[7]管明秀,周云丽,王 萌,等.TuM2-PK,tPSA,fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
 GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(04):140.
[8]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
 LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(04):93.
[9]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
 ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(04):99.
[10]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
 BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(04):103.

备注/Memo

备注/Memo:
作者简介 徐庆祝(1979-),男,主治医师,硕士在读,研究方向:泌尿外科临床;通信作者:牛远杰,E-mail:niuyuanjie9317@163.com
更新日期/Last Update: 2017-07-01